Portfolio News

Breye Therapeutics Secures €67.5 Million Series A Financing to Advance First-in-Class Oral Therapy for Diabetic Retinopathy Copenhagen (Denmark) – Golgi Neurosciences congratulates portfolio company Breye Therapeutics, a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases within ophthalmology, on the successful first close of its €67.5 million Series A financing round. The financing … Read more

Breye Therapeutics Publishes Groundbreaking Diabetic Retinopathy Research in Science Translational Medicine Copenhagen (Denmark) – Golgi Neurosciences is proud to announce that its portfolio company, Breye Therapeutics, a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases within ophthalmology, in collaboration with researchers at Trinity College Dublin, has published a groundbreaking study in Science … Read more

Muna Therapeutics Publishes Landmark Nature Medicine Study Highlighting Microglial Transitions as Drivers of Alzheimer’s Disease Copenhagen (Denmark) – Golgi Neurosciences is proud to announce that its portfolio company, Muna Therapeutics, a clinical-stage biotechnology company pioneering a new era of drug discovery for neurodegenerative diseases, has published a landmark study in Nature Medicine validating microglial state … Read more

Lario Therapeutics Secures $2.4M from The Michael J. Fox Foundation and Wellcome to Advance Neuronal Calcium Channel Platform for CNS Disorders Edinburgh (United Kingdom) – Golgi Neurosciences is honoured to announce that its portfolio company, Lario Therapeutics Ltd, a preclinical stage biotech developing first-in-class precision medicines targeting disease-modifying treatments for severe neurological disorders, has been … Read more

Muna Therapeutics Initiates Phase 1 Trial with First Participants Dosed for Novel Oral TREM2 Agonist Targeting Early Alzheimer’s Disease Copenaghen (Denmark) – Golgi Neurosciences Srl is pleased to announce that its portfolio company Muna Therapeutics, a clinical-stage biotechnology company developing innovative treatments for neurodegenerative diseases, has initiated a Phase 1 clinical study of its lead … Read more

Breye Therapeutics Reports Positive Phase 1b Results for Danegaptide, Supporting Progression to Phase 2 in Retinal Vascular Diseases Copenaghen (Denmark) – Golgi Neurosciences Srl is thrilled to share an update from its portfolio company Breye Therapeutics ApS, a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases within ophthalmology. Danegaptide is a first-in-class, … Read more

Alcatraz Therapeutics being awarded “New Company with more transformative potential” at Bio-Neurosciences 2025 Amsterdam (The Netherlands) – We are excited to share that Stefan Lohmer, ad interim CEO of Alcatraz Therapeutics, recently presented the company at BioNeuroscience 2025 in Amsterdam. Alcatraz Therapeutics has been honored with the “New Company with more transformative potential” award! Currently … Read more

Libra Therapeutics Advances LBR-2950 Program securing a $5 Million MJFF grant. San Diego (CA, USA) – Libra Therapeutics Inc., a Golgi Neuroscience’s Portfolio company developing novel therapeutics to restore cellular balance and attenuate neurodegeneration, has secured a $5 Million grant to advance the LBR-2950 program from the The Michael J. Fox Foundation for Parkinson’s Research … Read more

Muna Therapeutics Announces Strategic Alliance with GSK to Advance Alzheimer’s Research Copenaghen (Denmark) – Muna Therapeutics ApS, a Golgi Neuroscience’s portfolio company developing therapies that slow or stop devastating neurodegenerative diseases, has achieved a major milestone by forming a strategic alliance with GSK. This multi-year collaboration aims to slow or halt the progression of Alzheimer’s … Read more

Lario Therapeutics Secures $6 Million MJFF Grant for Groundbreaking Parkinson’s Research Edinburgh (United Kingdom) – Lario Therapeutics Ltd, a preclinical stage biotech and Golgi Neurosciences’ portfolio company developing first-in-class precision medicines targeting disease-modifying treatments for severe neurological disorders, has achieved a remarkable milestone by securing a $6 million grant from The Michael J. Fox Foundation … Read more